Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States

Results from the Patient and Provider Assessment of Lipid Management (PALM) registry

Michael G. Nanna, Ann Marie Navar, Tracy Y. Wang, Shuang Li, Salim S. Virani, Zhuokai Li, Jennifer G. Robinson, Veronique Lee Roger, Peter W.F. Wilson, Anne C. Goldberg, Andrew Koren, Michael J. Louie, Eric D. Peterson

Research output: Contribution to journalArticle

Abstract

Background: Adherence to guideline-recommended statin recommendations in the United States is suboptimal. Patients' likelihood to be treated according to guidelines may vary by the practice in which they are treated. Methods: Variation in the use of statin therapy in 5445 patients, with known or at high risk for atherosclerotic cardiovascular disease (ASCVD) and meeting a statin treatment indication, was examined across 74 US Patient and Provider Assessment of Lipid Management (PALM) Registry clinics. Multivariable generalized linear mixed modeling was used to determine the median odds ratio (MOR) for statin use and 2013 American College of Cardiology/American Heart Association guideline-recommended statin intensity by practice. MOR quantifies between-practice variation by comparing the odds of receiving guideline-recommended statin treatment in a patient from a randomly selected practice with a similar patient from another random practice. Risk-adjusted low-density lipoprotein cholesterol (LDL-C) control (<100 and <70 mg/dL) was compared among practice tertiles based on percentage of eligible patients receiving recommended statin intensity. Results: Among 74 practices (43.2% cardiology) comprised of 300 healthcare providers enrolling 5445 patients (56.2% with ASCVD), statin use at the guideline-recommended intensity at practices varied widely (12.7–71.4%; adjusted MOR 1.45, 95% confidence interval [CI] 1.35–1.64). Results were consistent when evaluated for any statin use overall (adjusted MOR 1.75, 95% CI 1.48–1.99) and when stratified by primary versus secondary prevention patients. Relative to practices with lowest or mid-tertile statin use of statins, highest tertile clinics were more frequently cardiology practices (68.0% vs 48.0% vs 12.5%, P < .001). Compared with lowest tertile clinics, patients at highest tertile clinics were more likely to achieve LDL-C <70 mg/dL (adjusted odds ratio [OR] 1.49, 95% CI 1.08–2.04) and <100 mg/dL (adjusted OR 1.78, 95% CI 1.41–2.25). Conclusions: US clinics varied widely in their adherence to guideline recommendations for statin therapy, which contributed to significant differences in LDL-C levels.

Original languageEnglish (US)
Pages (from-to)113-124
Number of pages12
JournalAmerican Heart Journal
Volume214
DOIs
StatePublished - Aug 1 2019

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
LDL Cholesterol
Registries
Lipids
Odds Ratio
Guidelines
Confidence Intervals
Guideline Adherence
Cardiology
Cardiovascular Diseases
Therapeutics
Secondary Prevention
Health Personnel

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States : Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. / Nanna, Michael G.; Navar, Ann Marie; Wang, Tracy Y.; Li, Shuang; Virani, Salim S.; Li, Zhuokai; Robinson, Jennifer G.; Roger, Veronique Lee; Wilson, Peter W.F.; Goldberg, Anne C.; Koren, Andrew; Louie, Michael J.; Peterson, Eric D.

In: American Heart Journal, Vol. 214, 01.08.2019, p. 113-124.

Research output: Contribution to journalArticle

Nanna, Michael G. ; Navar, Ann Marie ; Wang, Tracy Y. ; Li, Shuang ; Virani, Salim S. ; Li, Zhuokai ; Robinson, Jennifer G. ; Roger, Veronique Lee ; Wilson, Peter W.F. ; Goldberg, Anne C. ; Koren, Andrew ; Louie, Michael J. ; Peterson, Eric D. / Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States : Results from the Patient and Provider Assessment of Lipid Management (PALM) registry. In: American Heart Journal. 2019 ; Vol. 214. pp. 113-124.
@article{564ef2d4cae442e381f0188a5dd47c8f,
title = "Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States: Results from the Patient and Provider Assessment of Lipid Management (PALM) registry",
abstract = "Background: Adherence to guideline-recommended statin recommendations in the United States is suboptimal. Patients' likelihood to be treated according to guidelines may vary by the practice in which they are treated. Methods: Variation in the use of statin therapy in 5445 patients, with known or at high risk for atherosclerotic cardiovascular disease (ASCVD) and meeting a statin treatment indication, was examined across 74 US Patient and Provider Assessment of Lipid Management (PALM) Registry clinics. Multivariable generalized linear mixed modeling was used to determine the median odds ratio (MOR) for statin use and 2013 American College of Cardiology/American Heart Association guideline-recommended statin intensity by practice. MOR quantifies between-practice variation by comparing the odds of receiving guideline-recommended statin treatment in a patient from a randomly selected practice with a similar patient from another random practice. Risk-adjusted low-density lipoprotein cholesterol (LDL-C) control (<100 and <70 mg/dL) was compared among practice tertiles based on percentage of eligible patients receiving recommended statin intensity. Results: Among 74 practices (43.2{\%} cardiology) comprised of 300 healthcare providers enrolling 5445 patients (56.2{\%} with ASCVD), statin use at the guideline-recommended intensity at practices varied widely (12.7–71.4{\%}; adjusted MOR 1.45, 95{\%} confidence interval [CI] 1.35–1.64). Results were consistent when evaluated for any statin use overall (adjusted MOR 1.75, 95{\%} CI 1.48–1.99) and when stratified by primary versus secondary prevention patients. Relative to practices with lowest or mid-tertile statin use of statins, highest tertile clinics were more frequently cardiology practices (68.0{\%} vs 48.0{\%} vs 12.5{\%}, P < .001). Compared with lowest tertile clinics, patients at highest tertile clinics were more likely to achieve LDL-C <70 mg/dL (adjusted odds ratio [OR] 1.49, 95{\%} CI 1.08–2.04) and <100 mg/dL (adjusted OR 1.78, 95{\%} CI 1.41–2.25). Conclusions: US clinics varied widely in their adherence to guideline recommendations for statin therapy, which contributed to significant differences in LDL-C levels.",
author = "Nanna, {Michael G.} and Navar, {Ann Marie} and Wang, {Tracy Y.} and Shuang Li and Virani, {Salim S.} and Zhuokai Li and Robinson, {Jennifer G.} and Roger, {Veronique Lee} and Wilson, {Peter W.F.} and Goldberg, {Anne C.} and Andrew Koren and Louie, {Michael J.} and Peterson, {Eric D.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.ahj.2019.05.009",
language = "English (US)",
volume = "214",
pages = "113--124",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Practice-level variation in statin use and low-density lipoprotein cholesterol control in the United States

T2 - Results from the Patient and Provider Assessment of Lipid Management (PALM) registry

AU - Nanna, Michael G.

AU - Navar, Ann Marie

AU - Wang, Tracy Y.

AU - Li, Shuang

AU - Virani, Salim S.

AU - Li, Zhuokai

AU - Robinson, Jennifer G.

AU - Roger, Veronique Lee

AU - Wilson, Peter W.F.

AU - Goldberg, Anne C.

AU - Koren, Andrew

AU - Louie, Michael J.

AU - Peterson, Eric D.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - Background: Adherence to guideline-recommended statin recommendations in the United States is suboptimal. Patients' likelihood to be treated according to guidelines may vary by the practice in which they are treated. Methods: Variation in the use of statin therapy in 5445 patients, with known or at high risk for atherosclerotic cardiovascular disease (ASCVD) and meeting a statin treatment indication, was examined across 74 US Patient and Provider Assessment of Lipid Management (PALM) Registry clinics. Multivariable generalized linear mixed modeling was used to determine the median odds ratio (MOR) for statin use and 2013 American College of Cardiology/American Heart Association guideline-recommended statin intensity by practice. MOR quantifies between-practice variation by comparing the odds of receiving guideline-recommended statin treatment in a patient from a randomly selected practice with a similar patient from another random practice. Risk-adjusted low-density lipoprotein cholesterol (LDL-C) control (<100 and <70 mg/dL) was compared among practice tertiles based on percentage of eligible patients receiving recommended statin intensity. Results: Among 74 practices (43.2% cardiology) comprised of 300 healthcare providers enrolling 5445 patients (56.2% with ASCVD), statin use at the guideline-recommended intensity at practices varied widely (12.7–71.4%; adjusted MOR 1.45, 95% confidence interval [CI] 1.35–1.64). Results were consistent when evaluated for any statin use overall (adjusted MOR 1.75, 95% CI 1.48–1.99) and when stratified by primary versus secondary prevention patients. Relative to practices with lowest or mid-tertile statin use of statins, highest tertile clinics were more frequently cardiology practices (68.0% vs 48.0% vs 12.5%, P < .001). Compared with lowest tertile clinics, patients at highest tertile clinics were more likely to achieve LDL-C <70 mg/dL (adjusted odds ratio [OR] 1.49, 95% CI 1.08–2.04) and <100 mg/dL (adjusted OR 1.78, 95% CI 1.41–2.25). Conclusions: US clinics varied widely in their adherence to guideline recommendations for statin therapy, which contributed to significant differences in LDL-C levels.

AB - Background: Adherence to guideline-recommended statin recommendations in the United States is suboptimal. Patients' likelihood to be treated according to guidelines may vary by the practice in which they are treated. Methods: Variation in the use of statin therapy in 5445 patients, with known or at high risk for atherosclerotic cardiovascular disease (ASCVD) and meeting a statin treatment indication, was examined across 74 US Patient and Provider Assessment of Lipid Management (PALM) Registry clinics. Multivariable generalized linear mixed modeling was used to determine the median odds ratio (MOR) for statin use and 2013 American College of Cardiology/American Heart Association guideline-recommended statin intensity by practice. MOR quantifies between-practice variation by comparing the odds of receiving guideline-recommended statin treatment in a patient from a randomly selected practice with a similar patient from another random practice. Risk-adjusted low-density lipoprotein cholesterol (LDL-C) control (<100 and <70 mg/dL) was compared among practice tertiles based on percentage of eligible patients receiving recommended statin intensity. Results: Among 74 practices (43.2% cardiology) comprised of 300 healthcare providers enrolling 5445 patients (56.2% with ASCVD), statin use at the guideline-recommended intensity at practices varied widely (12.7–71.4%; adjusted MOR 1.45, 95% confidence interval [CI] 1.35–1.64). Results were consistent when evaluated for any statin use overall (adjusted MOR 1.75, 95% CI 1.48–1.99) and when stratified by primary versus secondary prevention patients. Relative to practices with lowest or mid-tertile statin use of statins, highest tertile clinics were more frequently cardiology practices (68.0% vs 48.0% vs 12.5%, P < .001). Compared with lowest tertile clinics, patients at highest tertile clinics were more likely to achieve LDL-C <70 mg/dL (adjusted odds ratio [OR] 1.49, 95% CI 1.08–2.04) and <100 mg/dL (adjusted OR 1.78, 95% CI 1.41–2.25). Conclusions: US clinics varied widely in their adherence to guideline recommendations for statin therapy, which contributed to significant differences in LDL-C levels.

UR - http://www.scopus.com/inward/record.url?scp=85067034150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067034150&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2019.05.009

DO - 10.1016/j.ahj.2019.05.009

M3 - Article

VL - 214

SP - 113

EP - 124

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -